Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25
Author Information
Author(s): Wu Yimin, Ellis Ruth D., Shaffer Donna, Fontes Erica, Malkin Elissa M., Mahanty Siddhartha, Fay Michael P., Narum David, Rausch Kelly, Miles Aaron P., Aebig Joan, Orcutt Andrew, Muratova Olga, Song Guanhong, Lambert Lynn, Zhu Daming, Miura Kazutoyo, Long Carole, Saul Allan, Miller Louis H., Durbin Anna P.
Primary Institution: Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases
Hypothesis
Can the Pfs25 and Pvs25 vaccines induce transmission blocking immunity in humans?
Conclusion
The Pfs25/ISA 51 vaccine can induce transmission blocking immunity in humans, but it is unexpectedly reactogenic.
Supporting Evidence
- Significant antibody responses were detected in volunteers who completed the lowest scheduled doses of Pfs25/ISA 51.
- Serum anti-Pfs25 levels correlated with transmission blocking activity.
- Two cases of erythema nodosum were reported, considered probably related to the vaccine.
Takeaway
This study tested two malaria vaccines to see if they could help stop the disease from spreading, and while they worked, they also caused some unexpected side effects.
Methodology
A single-blinded, dose-escalating, controlled Phase 1 trial with healthy volunteers receiving different doses of the vaccines.
Potential Biases
Potential bias in reporting adverse events due to the small sample size and early termination of the study.
Limitations
The study was stopped early due to unexpected reactogenicity, limiting the ability to assess long-term safety and efficacy.
Participant Demographics
Healthy males and non-pregnant females aged 18-50, with 47% Caucasian, 39% African American, 6% Hispanic, and 6% Asian.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website